リジェンセル・バイオサイエンス・ホールディングス
Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.01 | $0 | -$3M |
| 2025 Q4 | -0.00 | $0 | $0 |
| 2024 Q2 | -0.00 | $0 | $0 |
| 2024 Q4 | -0.00 | $0 | -$2M |
| 2023 Q2 | -0.00 | $0 | -$2M |
| 2023 Q4 | -0.01 | $0 | -$2M |
| 2022 Q2 |
| -0.01 |
| $0 |
| -$2M |
| 2022 Q4 | -0.01 | -$2.3B | -$3M |